T1	PrimaryOutcome 49 71	clinical recovery rate
T2	TimeFrame 72 113	at 7 days from the beginning of treatment
T3	OutcomeDefinition 148 443	continuous (>72 hours) recovery of body temperature, respiratory rate, oxygen saturation and cough relief after treatment, with following quantitative criteria: axillary temperature ≤36.6°C; respiratory frequency ≤24 times/min; Oxygen saturation ≥98% without oxygen inhalation; mild or no cough.
R1	MeasuredAt Arg1:T1 Arg2:T2	
R2	DefinedAs Arg1:T1 Arg2:T3	
T5	OtherOutcome 961 1032	adverse events occurred during treatment and premature discontinuation.
T7	SecondaryOutcome 661 679	rate of AOT or NMV
T8	SecondaryOutcome 681 700	all-cause mortality
T9	SecondaryOutcome 702 709	dyspnea
T11	SecondaryOutcome 878 934	rate of patients needed to receive intensive care in ICU
T10	SecondaryOutcome 711 738	rate of respiratory failure
T13	OutcomeDefinition 751 867	SPO2 ≤90% without oxygen inhalation or PaO2/FiO2 <300mmHg, requires oxygen therapy or additional respiratory support
R4	DefinedAs Arg1:T10 Arg2:T13	
T4	SecondaryOutcome 476 555	latency to pyrexia relief (for patients with pyrexia at the time of enrollment)
T6	SecondaryOutcome 561 655	latency to cough relief (for patients with moderate or severe cough at the time of enrollment)
